Richard E. Lowenthal - Jan 3, 2023 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/5/2023, 04:00 PM
Previous filing
Nov 10, 2022
Next filing
Jan 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +1.1M $0.00 1.1M Jan 3, 2023 Common Stock 1.1M $8.42 Direct F1
transaction SPRY Stock option (right to buy) Award $0 +350K $0.00 350K Jan 3, 2023 Common Stock 350K $8.42 By spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years.